Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose GW685698/GW642444 inhalation powder versus placebo in COPD
2008-000727-26Phase 2Completed
- Sponsor
- GSK
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GW685698 + GW642444 inhalation powder with Placebo inhalation powder (2 arms). Primary endpoint: Change from baseline in weighted mean heart rate 0–4 hours post-dose at day 28. Started May 2008; status: completed.
02
Drugs
fluticasone furoate + vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-000727-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000727-26.